• LAST PRICE
    2.0600
  • TODAY'S CHANGE (%)
    Trending Down-0.0650 (-3.0588%)
  • Bid / Lots
    2.0100/ 3
  • Ask / Lots
    2.1100/ 2
  • Open / Previous Close
    2.0912 / 2.1250
  • Day Range
    Low 2.0100
    High 2.1000
  • 52 Week Range
    Low 1.6900
    High 8.3000
  • Volume
    4,132
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 2.125
TimeVolumeCYTH
09:32 ET19502.0912
09:38 ET1002.07
09:39 ET2782.06
10:30 ET8802.1
10:35 ET4002.06
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCYTH
Cyclo Therapeutics Inc
14.6M
-1.2x
---
United StatesTTNP
Titan Pharmaceuticals Inc
15.6M
-1.3x
---
United StatesLEXX
Lexaria Bioscience Corp
14.3M
-2.0x
---
United StatesNXGL
Nexgel Inc
8.9M
-1.6x
---
United StatesSBFM
Sunshine Biopharma Inc
15.6M
-0.5x
---
United StatesNLBS
Nutralife Biosciences Inc
12.4M
-2.7x
---
As of 2022-10-05

Company Information

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta-cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. Its products include Trappsol HPB and Trappsol other product. The Company also operates a fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Contact Information

Headquarters
6714 Nw 16Th Street,, Suite BGAINESVILLE, FL, United States 32653
Phone
386-418-8060
Fax
---

Executives

Independent Chairman of the Board
Markus Sieger
Chief Executive Officer, Director
N. Scott Fine
Independent Vice Chairman of the Board
F. Patrick Ostronic
Founder, Independent Director
C.E. Strattan
Chief Financial Officer, Secretary
Joshua Fine

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.6M
Revenue (TTM)
$1.7M
Shares Outstanding
8.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.52
EPS
$-1.72
Book Value
$1.86
P/E Ratio
-1.2x
Price/Sales (TTM)
8.5
Price/Cash Flow (TTM)
---
Operating Margin
-746.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.